Selecting MYB–NFIB and MYBL1–NFIB junction peptides for experimental testing in adenoid cystic carcinoma

Abstract

This repository contains data and code accompanying “Selecting MYB–NFIB and MYBL1–NFIB junction peptides for experimental testing in adenoid cystic carcinoma.” The study screens 102 RNA-sequencing libraries to identify fusion-junction sequences, assess HLA assignments, and prioritize candidate HLA class I peptides for experimental testing. Twenty-eight libraries supported peptide–HLA prediction. The final shortlist comprises 47 peptide–HLA pairs involving 30 peptide sequences across 22 libraries. An initial experimental panel includes eight peptide–HLA pairs representing seven sequences, supported by 11 libraries. Version 9 adds aggregate genetic evidence supporting at least 10 distinct donors among the 11 panel libraries. Six of the eight panel pairs have support in at least two genetically distinct donors. These minimum donor counts are unchanged across 24 sensitivity analyses. Repeat libraries with evidence of a common donor origin are not counted as independent donors. The underlying prediction outputs and primary candidate selection remain unchanged from analysis version 8.8.17. The archive includes prediction and selection tables, a supplementary analysis workbook, figures, analysis and figure-generation code, aggregate donor-support tables, and documentation. Individual genetic fingerprints, library-pair relationship classifications, raw sequencing reads, and licensed prediction software are not included. The public aggregate tables do not independently reproduce the underlying donor-identity evidence. These results prioritize candidates for experimental testing; they do not establish natural presentation by tumor cells or T-cell recognition. Donor counts are genetically supported lower bounds, not clinically confirmed patient identities.